Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis

Kang,Jingbo; Nie,Qing; Du,Rui; Zhang,Liping; Zhang,Jun; Li,Qiliang; Li,Jianguo; Qi,Wenjie

doi:10.3892/mco.2013.196

Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis

Authors:
- Jingbo Kang
- Qing Nie
- Rui Du
- Liping Zhang
- Jun Zhang
- Qiliang Li
- Jianguo Li
- Wenjie Qi
View Affiliations

Affiliations: Department of Radiotherapy, Navy General Hospital, Beijing 100048, P.R. China
Published online on: September 30, 2013 https://doi.org/10.3892/mco.2013.196
Pages: 43-50

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of this study was to evaluate the clinical efficacy, toxicity and adverse effects of stereotactic body radiotherapy (SBRT) combined with transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). A total of 101 patients diagnosed with primary HCC with PVTT were enrolled in this study and were randomly divided into three groups as follows: group A, 34 patients treated with γ‑SBRT followed by TACE; group B, 37 patients treated with TACE followed by γ‑SBRT; and group C, 30 patients treated with γ‑SBRT alone. The effective response rate for the entire patient sample was 87.1% (88/101) following a 3‑month treatment. The differences in the response rate, survival rate, α‑fetoprotein level restoration rate and rate of improvement of abdominal distention and discomfort between groups A and B were not statistically significant (P>0.05). However, the rates of groups A and B were higher compared to those of group C (P<0.05). The exacerbation rate of liver function in group A was lower compared to that in group B (P<0.05), although it exhibited no statistically significant difference from that in group C (P>0.05). No severe radiation‑related complications were reported during the follow‑up period. The combination of γ‑SBRT and TACE was shown to be a relatively effective local treatment for primary HCC patients with PVTT. Compared to γ‑SBRT followed by TACE and γ‑SBRT alone, TACE followed by γ‑SBRT may exert a negative effect on liver function. These results suggested that the combination of TACE and γ‑SBRT may be considered a relatively effective, safe and feasible treatment method for primary HCC patients with PVTT, although TACE followed by γ‑SBRT may negatively affect liver function.

View Figures

View References

1.	Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 6:674–687. 2006. View Article : Google Scholar : PubMed/NCBI
2.	Yang HI, Lu SN, Liaw YF, et al: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 347:168–174. 2002. View Article : Google Scholar : PubMed/NCBI
3.	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
4.	Llovet JM: Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 40:225–235. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A and Camma C: A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 51:1274–1283. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Kim JH, Yoon HK, Kim SY, et al: Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther. 29:1291–1298. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Kothary N, Weintraub JL, Susman J and Rundback JH: Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol. 18:1517–1527. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Chung YH, Song IH, Song BC, et al: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer. 88:1986–1991. 2000. View Article : Google Scholar
9.	Obi S, Yoshida H, Toune R, et al: Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 106:1990–1997. 2006. View Article : Google Scholar : PubMed/NCBI
10.	Emami B, Lyman J, Brown A, et al: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 21:109–122. 1991. View Article : Google Scholar : PubMed/NCBI
11.	Krishnan S, Dawson LA, Seong J, et al: Radiotherapy for hepatocellular carcinoma: an overview. Ann Surg Oncol. 15:1015–1024. 2008. View Article : Google Scholar : PubMed/NCBI
12.	Price TR, Perkins SM, Sandrasegaran K, et al: Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer. 118:3191–3198. 2012. View Article : Google Scholar : PubMed/NCBI
13.	Facciuto ME, Singh MK, Rochon C, et al: Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. J Surg Oncol. 105:692–698. 2012. View Article : Google Scholar : PubMed/NCBI
14.	Tse RV, Hawkins M, Lockwood G, et al: Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 26:657–664. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Choi BO, Choi IB, Jang HS, et al: Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer. 8:3512008. View Article : Google Scholar
16.	Zhao M, Wang JP, Li W, et al: Comparison of safety and efficacy for transcatheter arterial chemoembolization alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and their prognosis factors. Zhonghua Yi Xue Za Zhi. 91:1167–1172. 2011.(In Chinese).
17.	Dawson LA, Eccles C and Craig T: Individualized image guided iso-NTCP based liver cancer SBRT. Acta Oncol. 45:856–864. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD and Fajardo LF: Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 31:1237–1248. 1995. View Article : Google Scholar : PubMed/NCBI
19.	Lo SS, Dawson LA, Kim EY, et al: Stereotactic body radiation therapy for hepatocellular carcinoma. Discov Med. 9:404–410. 2010.PubMed/NCBI
20.	Sawrie SM, Fiveash JB and Caudell JJ: Stereotactic body radiation therapy for liver metastases and primary hepatocellular carcinoma: normal tissue tolerances and toxicity. Cancer Control. 17:111–119. 2010.PubMed/NCBI
21.	Izaki K, Sugimoto K, Sugimura K and Hirota S: Transcatheter arterial embolization for advanced tumor thrombus with marked arterioportal or arteriovenous shunt complicating hepatocellular carcinoma. Radiat Med. 22:155–162. 2004.
22.	Li Q, Zeng CJ and Wang Y: Interventional chemoembolization combined with proton radiotherapy for the treatment of hepatocellular carcinoma accompanied with portal cancerous thrombus. J Intervent Radiol. 18:278–280. 2009.
23.	Seong J, Park HC, Han KH, et al: Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatol Res. 27:30–35. 2003. View Article : Google Scholar
24.	Ren B, Song JB, Wang XD, et al: Stereotactic radiotherapy for hepatocellular carcinoma with portal tumor thrombi. Chin J Hepatol. 14:308–309. 2006.(In Chinese).
25.	Dang YZ, Zhang XC, Lu WL, et al: Body gamma knife and high intensity focused ultrasound (HIFU) for the treatment of portal vein tumor thrombosis of hepatocellular carcinoma. J Mod Oncol. 18:114–117. 2010.